Drug Discovery Informatics Market Report by Workflow, Function, Mode, End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organization, and Others), and Region 2024-2032
세계의 Drug Discovery 인포매틱스 시장 규모는 2023년 33억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 78억 달러에 이를 전망이며 예측 기간 동안 9.7%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다.
의약품 정보학은 대량의 생화학 데이터를 분석하고 해석하는 데 사용되는 기술 솔루션입니다. 데이터는 연구 목적으로 임상 실험실에서 실시한 실험에서 생성되며 다양한 의약품 개발에 대한 인사이트을 얻기 위해 사용됩니다. 시퀀싱, 대상 데이터 분석, 데이터 시각화, 도킹, 분자 모델링, 신약 개발을 위한 데이터베이스 보호 등 많은 소프트웨어 및 하드웨어 기반 도구가 포함됩니다. 그 결과, 의료기관, 제약,바이오테크놀러지 기관, CRO(의약품 개발 업무 수탁 기관) 등에서 널리 이용되고 있습니다.
세계의 의료 및 제약 업계의 현저한 성장은 시장의 밝은 전망을 만드는 주요 요인 중 하나입니다. 게다가 만성질환의 유병률 증가와 희귀질환을 치료하기 위한 효과적인 솔루션에 대한 요구 증가도 시장의 성장을 뒷받침하고 있습니다. 의약품 정보학은 신약 분석 및 여러 출처의 생물학적 정보를 처리하기 위해 제약 회사에서 널리 사용됩니다. 또한 모델링과 시뮬레이션을 통해 약동학 결과의 예측을 지원하는 혁신적인 생리학적 약동학(PBPK) 시뮬레이터 플랫폼 개발 등 다양한 기술적 진보도 성장을 가속하는 요인이 되고 있습니다. 이에 따라 오펀 드래그 개발을 위한 정부와 민간 의료기관의 투자 증가도 시장 성장에 기여하고 있습니다. 기타 요인으로는 노인 인구 증가, 바이오인포매틱스 부문의 광범위한 연구개발(R&D) 활동 등이 있어 시장의 추가 견인역이 될 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 세계의 Drug Discovery 인포매틱스 시장은 지금까지 어떻게 추이해, 향후 어떻게 추이해 갈 것인가?
- COVID-19가 세계의 Drug Discovery 인포매틱스 시장에 미친 영향은?
- 주요 지역 시장은?
- 워크플로우별 시장 분석은?
- 기능별 시장 분석은?
- 모드별 시장 분석은?
- 최종 사용자별 시장 분석은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인과 도전은 무엇인가?
- 세계의 Drug Discovery 인포매틱스 시장의 구조와 주요 진출기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 Drug Discovery 인포매틱스 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석: 워크플로우별
제7장 시장 분석 : 기능별
- 배열 분석 플랫폼
- 분자 모델링
- 분자 도킹
- 임상시험 데이터 관리
- 기타
제8장 시장 분석 : 모드별
제9장 시장 내역: 최종 사용자별
- 제약회사
- 바이오테크놀러지 기업
- 연구기관(CRO)
- 기타
제10장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Accenture PLC
- Certara
- Charles River Laboratories Inc.
- Collaborative Drug Discovery Inc.
- Eurofins DiscoverX Products
- Infosys Ltd.
- International Business Machines Corporation
- Jubilant Biosys Limited
- Oracle Corporation
- PerkinElmer Inc.
- Selvita
- Thermo Fisher Scientific Inc.
BJH
The global drug discovery informatics market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032.
Drug discovery informatics is a technological solution used for analyzing and interpreting large volumes of biochemical data. The data is generated from the experiments conducted in clinical laboratories for research purposes and utilized for generating insights regarding the development of various drugs. It involves numerous software and hardware-based tools for sequencing, target data analysis, data visualization, docking, molecular modelling, database protection for drug discovery and development. As a result, it is widely used by healthcare institutions, pharmaceutical and biotechnology organizations and contract research organizations (CROs).
Significant growth in the healthcare and pharmaceutical industries across the globe represents one of key the factors creating a positive outlook for the market. Furthermore, the increasing prevalence of chronic medical disorders and the escalating requirement for effective solutions to treat rare diseases are also augmenting the market growth. Drug discovery informatics is widely used by pharmaceutical organizations for the analysis of new drug entities and handling of the biological information from multiple sources. Additionally, various technological advancements, such as the development of innovative Physiologically-based Pharmacokinetic (PBPK) Simulator platforms, which aid in predicting pharmacokinetic outcomes through modeling and simulation, are acting as other growth-inducing factors. In line with this, increasing investments by government and private healthcare institutions to develop orphan drugs is also contributing to the market growth. Other factors, including the rising geriatric population, along with extensive research and development (R&D) activities in the field of bioinformatics, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global drug discovery informatics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on workflow, function, mode and end user.
Breakup by Workflow:
Drug Discovery
Drug Development
Breakup by Function:
Sequence Analysis Platforms
Molecular Modelling
Molecular Docking
Clinical Trial Data Management
Others
Breakup by Mode:
Outsourced
In-house
Breakup by End User:
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organization (CROs)
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture Plc, Certara, Charles River Laboratories Inc., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products, Infosys Ltd., International Business Machines Corporation, Jubilant Biosys Limited, Oracle Corporation, PerkinElmer Inc., Selvita and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
- How has the global drug discovery informatics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global drug discovery informatics market?
- What are the key regional markets?
- What is the breakup of the market based on the workflow?
- What is the breakup of the market based on the function?
- What is the breakup of the market based on the mode?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global drug discovery informatics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Drug Discovery Informatics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Workflow
- 6.1 Drug Discovery
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Drug Development
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Function
- 7.1 Sequence Analysis Platforms
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Molecular Modelling
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Molecular Docking
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Clinical Trial Data Management
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Mode
- 8.1 Outsourced
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 In-house
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by End User
- 9.1 Pharmaceutical Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Biotechnology Companies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Contract Research Organization (CROs)
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Accenture PLC
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Certara
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Charles River Laboratories Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Collaborative Drug Discovery Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Eurofins DiscoverX Products
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Infosys Ltd.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 International Business Machines Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Jubilant Biosys Limited
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Oracle Corporation
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 PerkinElmer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Selvita
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.12 Thermo Fisher Scientific Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
